Telatinib + Keytruda for Stomach and Liver Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a combination of two drugs, telatinib and Keytruda, in patients with advanced stomach, gastroesophageal junction cancer, and liver cancer. Telatinib aims to stop cancer growth, while Keytruda helps the immune system fight the cancer. The goal is to see if this combination can help patients live longer without their cancer worsening.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, if you are on systemic steroid therapy or immunosuppressive therapy, you may need to stop these at least 7 days before starting the trial treatment.
Is the combination of Telatinib and Keytruda safe for humans?
Keytruda (Pembrolizumab) has been used in various cancer treatments and is generally considered safe, but it can cause side effects like fatigue, nausea, and immune-related issues such as pneumonitis (lung inflammation) and type 1 diabetes in rare cases. There is no specific safety data available for the combination of Telatinib and Keytruda, but Keytruda's safety profile is well-documented in other conditions.12345
What makes the drug combination of Telatinib and Keytruda unique for treating stomach and liver cancer?
What data supports the effectiveness of the drug Keytruda (pembrolizumab) for stomach and liver cancer?
Who Is on the Research Team?
Andrew Hendifar, MD
Principal Investigator
Cedars-Sinai Medical Center
Are You a Good Fit for This Trial?
Adults with advanced stomach, gastroesophageal junction cancers or hepatocellular carcinoma that have progressed after prior treatments and are PD-L1-positive. They must be able to swallow tablets, not have uncontrolled infections or certain other health conditions, and agree to use contraception.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive telatinib in combination with Keytruda
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Keytruda
- Telatinib
Keytruda is already approved in United States, European Union, Japan, Canada for the following indications:
- Melanoma
- Non-small cell lung cancer
- Head and neck squamous cell carcinoma
- Urothelial carcinoma
- Colorectal cancer
- Gastric cancer
- Hepatocellular carcinoma
- Merkel cell carcinoma
- Renal cell carcinoma
- Cervical cancer
- Endometrial carcinoma
- Esophageal cancer
- Triple-negative breast cancer
- Melanoma
- Non-small cell lung cancer
- Urothelial carcinoma
- Head and neck squamous cell carcinoma
- Hepatocellular carcinoma
- Renal cell carcinoma
- Colorectal cancer
- Gastric cancer
- Cervical cancer
- Endometrial carcinoma
- Esophageal cancer
- Triple-negative breast cancer
- Melanoma
- Non-small cell lung cancer
- Urothelial carcinoma
- Head and neck squamous cell carcinoma
- Hepatocellular carcinoma
- Renal cell carcinoma
- Colorectal cancer
- Gastric cancer
- Melanoma
- Non-small cell lung cancer
- Urothelial carcinoma
- Head and neck squamous cell carcinoma
- Hepatocellular carcinoma
- Renal cell carcinoma
- Colorectal cancer
- Gastric cancer
- Cervical cancer
- Endometrial carcinoma
- Esophageal cancer
- Triple-negative breast cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
Andrew Hendifar, MD
Lead Sponsor
EOC Pharma
Industry Sponsor
EOC Pharma
Collaborator